BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol. 2001;34:584-586. [PMID: 11394659 DOI: 10.1016/s0168-8278(00)00023-4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Umeoka F, Iwasaki Y, Matsumura M, Takaki A, Kobashi H, Tatsukawa M, Shiraha H, Fujioka S, Sakaguchi K, Shiratori Y. Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients. J Gastroenterol 2006;41:693-701. [PMID: 16933008 DOI: 10.1007/s00535-006-1834-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
2 Yang JH, Zhang H, Chen XB, Chen G, Wang X. Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. World J Gastroenterol 2013; 19(24): 3861-3865 [PMID: 23840126 DOI: 10.3748/wjg.v19.i24.3861] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
3 Kim DY, Chang HY, Lim SM, Kim SU, Park JY, Kim JK, Lee KS, Han KH, Chon CY, Ahn SH. Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B. Gut Liver 2013;7:329-34. [PMID: 23710315 DOI: 10.5009/gnl.2013.7.3.329] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
4 Choi YM, Lee SY, Kim BJ. Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression. World J Gastroenterol 2018; 24(16): 1708-1724 [PMID: 29713126 DOI: 10.3748/wjg.v24.i16.1708] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
5 Lee CZ, Lee HS, Huang GT, Yang PM, Sheu JC. Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol 2006; 12(33): 5301-5305 [PMID: 16981258 DOI: 10.3748/wjg.v12.i33.5301] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
6 Rybicka M, Stalke P, Dreczewski M, Smiatacz T, Bielawski KP. High-throughput matrix-assisted laser desorption ionization-time of flight mass spectrometry as an alternative approach to monitoring drug resistance of hepatitis B virus. J Clin Microbiol 2014;52:9-14. [PMID: 24068014 DOI: 10.1128/JCM.01891-13] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Jang H, Cho M, Heo J, Kim H, Jun H, Shin W, Cho B, Park H, Kim C. Oligonucleotide chip for detection of Lamivudine-resistant hepatitis B virus. J Clin Microbiol. 2004;42:4181-4188. [PMID: 15365009 DOI: 10.1128/jcm.42.9.4181-4188.2004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
8 Qu JX, Zeng QL, Liu ZG, Xu GH, Feng JH, Zhao PD, Gao XH, Wang T, Ren YQ. Spontaneous HBV YMDD motif mutations in patients with familially clustered chronic HBV infection. Shijie Huaren Xiaohua Zazhi 2010; 18(24): 2604-2607 [DOI: 10.11569/wcjd.v18.i24.2604] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Huang ZM, Huang QW, Qin YQ, Huang CH, Qin HJ, Zhou YN, Xu X, Lu CL. Clinical characteristics and distribution of hepatitis B virus genotypes in Guangxi Zhuang population. World J Gastroenterol 2005; 11(41): 6525-6529 [PMID: 16425428 DOI: 10.3748/wjg.v11.i41.6525] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
10 Zheng J, Zeng Z, Zhang D, Yu Y, Wang F, Pan CQ. Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients. Liver Int. 2012;32:1535-1542. [PMID: 22882650 DOI: 10.1111/j.1478-3231.2012.02859.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
11 Yang ZJ, Tu MZ, Liu J, Wang XL, Jin HZ. Comparison of amplicon-sequencing, pyrosequencing and real-time PCR for detection of YMDD mutants in patients with chronic hepatitis B. World J Gastroenterol 2006; 12(44): 7192-7196 [PMID: 17131486 DOI: 10.3748/wjg.v12.i44.7192] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
12 Wang XL, Xie SG, Zhang L, Yang WX, Wang X, Jin HZ. Comparison of ligase detection reaction and real-time PCR for detection of low abundant YMDD mutants in patients with chronic hepatitis B. World J Gastroenterol 2008; 14(1): 120-124 [PMID: 18176973 DOI: 10.3748/wjg.14.120] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
13 Lin CL, Tsai SL, Lee TH, Chien RN, Liao SK, Liaw YF. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B. Gut 2005;54:152-61. [PMID: 15591521 DOI: 10.1136/gut.2003.032920] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
14 Yıldız O, Aygen B, Demirtürk N, Demirdal T, Inan D, Yıldırmak T, Kantürk A, Tütüncü E, Group HBS. Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. World J Gastroenterol 2011; 17(45): 4987-4992 [PMID: 22174548 DOI: 10.3748/wjg.v17.i45.4987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
15 Ma Y, Yuan Y, Ma X, Tang B, Hu X, Feng J, Tian L, Ji Y, Dou X. Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy. Exp Ther Med 2016;12:847-53. [PMID: 27446286 DOI: 10.3892/etm.2016.3365] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Li MW, Hou W, Wo JE, Liu KZ. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance. J Zhejiang Univ Sci B. 2005;6:664-667. [PMID: 15973769 DOI: 10.1631/jzus.2005.b0664] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Kurashige N, Hiramatsu N, Ohkawa K, Yakushijin T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Oshita M, Mita E, Hagiwara H, Nagase T, Yoshihara H, Hayashi E, Imai Y, Kato M, Kashihara T, Hayashi N. Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol 2009;44:601-7. [PMID: 19387534 DOI: 10.1007/s00535-009-0038-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
18 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2006; 14(19): 1853-1858 [DOI: 10.11569/wcjd.v14.i19.1853] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Tan Y, Ding K, Su J, Trinh X, Peng Z, Gong Y, Chen L, Cui Q, Lei N, Chen X, Yu R. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: A systematic review and meta-analysis. PLoS One. 2012;7:e32789. [PMID: 22479339 DOI: 10.1371/journal.pone.0032789] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
20 Zöllner B, Sterneck M, Wursthorn K, Petersen J, Schröter M, Laufs R, Feucht HH. Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy. J Clin Microbiol 2005;43:2503-5. [PMID: 15872296 DOI: 10.1128/JCM.43.5.2503-2505.2005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
21 Qu JX, Zeng QL, Xu GH. Advances in research on natural YMDD mutations in the hepatitis B virus DNA polymerase in patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2010; 18(9): 902-905 [DOI: 10.11569/wcjd.v18.i9.902] [Reference Citation Analysis]
22 Zhang YY, Hu KQ, Duan Z. New perspective on the natural course of chronic HBV infection. Front Med 2014;8:129-34. [PMID: 24871442 DOI: 10.1007/s11684-014-0339-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Moehlen M, De Medina M, Hill M, Jeffers L, Schiff ER, Martin P. Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy. ISRN Hepatol 2013;2013:130384. [PMID: 27335823 DOI: 10.1155/2013/130384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
24 Marino A, Cosentino F, Ceccarelli M, Moscatt V, Pampaloni A, Scuderi D, D'Andrea F, Rullo EV, Nunnari G, Benanti F, Celesia BM, Cacopardo B. Entecavir resistance in a patient with treatment-naïve HBV: A case report. Mol Clin Oncol 2021;14:113. [PMID: 33903819 DOI: 10.3892/mco.2021.2275] [Reference Citation Analysis]
25 Fang J, Wichroski MJ, Levine SM, Baldick CJ, Mazzucco CE, Walsh AW, Kienzle BK, Rose RE, Pokornowski KA, Colonno RJ, Tenney DJ. Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates. Antimicrob Agents Chemother 2009;53:2762-72. [PMID: 19433559 DOI: 10.1128/AAC.00130-09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Huang ZM, Huang QW, Qin YQ, He YZ, Qin HJ, Zhou YN, Xu X, Huang MJ. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 2005; 11(6): 867-870 [PMID: 15682483 DOI: 10.3748/wjg.v11.i6.867] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
27 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(7): 1674-1677 [DOI: 10.11569/wcjd.v12.i7.1674] [Reference Citation Analysis]
28 Dan YY, Wai CT, Lee YM, Sutedja DS, Seet BL, Lim SG. Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World J Gastroenterol 2005; 11(28): 4344-4350 [PMID: 16038032 DOI: 10.3748/wjg.v11.i28.4344] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]